The air is getting thinner for US technology titans. After last year's stock price rally, investors expect nothing less than perfection from the «Magnificent Seven», as a review of the quarterly results reveals.
About four months ago, Sandoz was spun off from its parent company Novartis. The success of the Swiss drugmaker is likely to be determined by its performance in the growing biosimilars market.
After a difficult few months, Lonza shares have made a brilliant start to the new year.
Tesla's disappointing quarterly results put pressure on the shares of the electric car manufacturer.
In the coming days and weeks, Wall Street will be monitoring company results closely. The «Magnificent Seven» are likely to attract particular attention as their shares have risen sharply in 2023.
Bonus Certificate Nestlé, Novartis und Roche
«ZKB Favourite Stocks 2024»: Building Exposure with Reverse Convertibles
The research at Zürcher Kantonalbank has identified ten equity top picks for the new year. The tracker certificate on the «ZKB Favourite Stocks 2024» allows investors to participate in this selection.
ZKB Callable Barrier Reverse Convertible on worst of Vale SA/Starbucks Corp/Adobe Inc 132912438 / CH1329124387 |
ZKB Callable Barrier Reverse Convertible on worst of SunPower Corp/Sunrun Inc 127344767 / CH1273447677 |
ZKB Autocallable Barrier Reverse Convertible auf ON Holding AG 127345566 / CH1273455662 |
ZKB Callable Barrier Reverse Convertible on worst of Swisscom AG/Kuehne + Nagel International AG/Sik... 130397238 / CH1303972389 |
ZKB Barrier Reverse Convertible on worst of ABB Ltd/Swisscom AG/Roche Holding AG/Swiss Re AG 127347485 / CH1273474853 |